Technology evaluation: denosumab, Amgen.
Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.
Abrahamsen
Bo
B
Copenhagen University, RASK Osteoporosis Clinic, Department of Medicine, Roskilde County Hospital Koge, Denmark. b.abrahamsen@dadlnet.dk
Teng
Andy Y T
AY
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000096:biosynthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D000069448:Denosumab; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D006801:Humans; D010330:Patents as Topic; D053245:RANK Ligand
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab